Immunotherapy versus standard chemotherapy for treatment of extensive-stage small-cell lung cancer: a systematic review.
Immunotherapy
; 13(12): 989-1000, 2021 08.
Article
in En
| MEDLINE
| ID: mdl-34114477
Lay abstract In the past decades, therapy of small-cell lung cancer (SCLC) has maintained the status quo in that etoposide, in combination with platinum-based chemotherapy, is still the first-line treatment for SCLC. Despite cancer cells being very sensitive to standard chemotherapy, relapse rates and prognosis are poor, especially in extensive-stage small-cell lung carcinoma (ES-SCLC). It is meaningful that immune checkpoint inhibitors have led to a promising transformation of treatment models for ES-SCLC. We searched the related literature systematically and performed a meta-analysis of several clinical trials to compare chemotherapy's therapeutic efficacy with immunotherapy. We found that immune checkpoint inhibitors achieve great improvement in survival indexes of ES-SCLC patients compared with standard chemotherapy.
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Small Cell Lung Carcinoma
/
Immune Checkpoint Inhibitors
/
Immunotherapy
/
Lung Neoplasms
Type of study:
Systematic_reviews
Limits:
Humans
Language:
En
Journal:
Immunotherapy
Journal subject:
ALERGIA E IMUNOLOGIA
/
TERAPEUTICA
Year:
2021
Document type:
Article
Affiliation country:
China
Country of publication:
United kingdom